Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: Serum trefoil factor 3 is a stable biomarker

Mitsuru Kaise, Jun Miwa, Ai Fujimoto, Jun Tashiro, Daisuke Tagami, Hiromi Sano, Yasukazu Ohmoto

研究成果: Article

18 引用 (Scopus)

抄録

Background and aim: Emerging data indicate that serum trefoil factors (TFFs), especially TFF3, could be potential biomarkers for gastric cancer risk. We aimed to evaluate the influence of Helicobacter pylori (H. pylori) status and eradication on serum TFFs and the pepsinogen test. Methods: Healthy individuals who underwent a thorough medical checkup were enrolled in study 1, and gastric ulcer patients who undertook H. pylori eradication therapy were enrolled in studies 2 and 3. Serum levels of the TFFs (TFF1, TFF2 and TFF3), H. pylori antibody and pepsinogen test were examined in all studies. In study 3, TFF expressions in biopsy samples of the gastric mucosa were additionally examined before and 2 months after eradication. Results: In 1,260 healthy individuals enrolled in study 1, serum TFF1 and TFF2 levels were markedly different between H. pylori antibody-positive and -negative participants (P < 0.0001). Differences in serum TFF3 levels between H. pylori antibody-positive (5.85 ± 3.93 ng/ml) and -negative subjects (5.27 ± 2.38 ng/ml) were statistically significant (P = 0.002) but small in absolute value. In 178 gastric ulcer patients enrolled in study 2, serum TFF1, TFF2 and positive rates of the pepsinogen test significantly decreased 2 months after H. pylori eradication therapy (P < 0.001). In contrast, serum TFF3 levels and positive rates of high TFF3 levels (≥7 ng/ml) did not significantly change with H. pylori-eradication until 5 years after eradication. In 18 gastric ulcer patients (study 3), TFF1 and TFF2 were mainly expressed in the foveolar epithelium, and TFF2 was additionally expressed in the pyloric glands. These expressions significantly decreased with H. pylori eradication. TFF3s were scarcely expressed in the gastric mucosa except in goblet cells of intestinal metaplasia, which did not change with H. pylori eradication. Conclusion: In serum TFFs and pepsinogen tests, only serum TFF3s were not significantly affected by H. pylori eradication, suggesting that serum TFF3 could be a stable biomarker of gastric cancer risk even after H.pylori eradication in contrast with the pepsinogen test.

元の言語English
ページ(範囲)329-337
ページ数9
ジャーナルGastric Cancer
16
発行部数3
DOI
出版物ステータスPublished - 2013 7
外部発表Yes

Fingerprint

Pepsinogen A
Helicobacter pylori
Biomarkers
Serum
Stomach Ulcer
Gastric Mucosa
Stomach Neoplasms
Antibodies
Trefoil Factors
Trefoil Factor-3
Goblet Cells
Pylorus
Metaplasia
Epithelium

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

これを引用

Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test : Serum trefoil factor 3 is a stable biomarker. / Kaise, Mitsuru; Miwa, Jun; Fujimoto, Ai; Tashiro, Jun; Tagami, Daisuke; Sano, Hiromi; Ohmoto, Yasukazu.

:: Gastric Cancer, 巻 16, 番号 3, 07.2013, p. 329-337.

研究成果: Article

Kaise, Mitsuru ; Miwa, Jun ; Fujimoto, Ai ; Tashiro, Jun ; Tagami, Daisuke ; Sano, Hiromi ; Ohmoto, Yasukazu. / Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test : Serum trefoil factor 3 is a stable biomarker. :: Gastric Cancer. 2013 ; 巻 16, 番号 3. pp. 329-337.
@article{fdcdfc81c7a447358652e62042bb22a9,
title = "Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: Serum trefoil factor 3 is a stable biomarker",
abstract = "Background and aim: Emerging data indicate that serum trefoil factors (TFFs), especially TFF3, could be potential biomarkers for gastric cancer risk. We aimed to evaluate the influence of Helicobacter pylori (H. pylori) status and eradication on serum TFFs and the pepsinogen test. Methods: Healthy individuals who underwent a thorough medical checkup were enrolled in study 1, and gastric ulcer patients who undertook H. pylori eradication therapy were enrolled in studies 2 and 3. Serum levels of the TFFs (TFF1, TFF2 and TFF3), H. pylori antibody and pepsinogen test were examined in all studies. In study 3, TFF expressions in biopsy samples of the gastric mucosa were additionally examined before and 2 months after eradication. Results: In 1,260 healthy individuals enrolled in study 1, serum TFF1 and TFF2 levels were markedly different between H. pylori antibody-positive and -negative participants (P < 0.0001). Differences in serum TFF3 levels between H. pylori antibody-positive (5.85 ± 3.93 ng/ml) and -negative subjects (5.27 ± 2.38 ng/ml) were statistically significant (P = 0.002) but small in absolute value. In 178 gastric ulcer patients enrolled in study 2, serum TFF1, TFF2 and positive rates of the pepsinogen test significantly decreased 2 months after H. pylori eradication therapy (P < 0.001). In contrast, serum TFF3 levels and positive rates of high TFF3 levels (≥7 ng/ml) did not significantly change with H. pylori-eradication until 5 years after eradication. In 18 gastric ulcer patients (study 3), TFF1 and TFF2 were mainly expressed in the foveolar epithelium, and TFF2 was additionally expressed in the pyloric glands. These expressions significantly decreased with H. pylori eradication. TFF3s were scarcely expressed in the gastric mucosa except in goblet cells of intestinal metaplasia, which did not change with H. pylori eradication. Conclusion: In serum TFFs and pepsinogen tests, only serum TFF3s were not significantly affected by H. pylori eradication, suggesting that serum TFF3 could be a stable biomarker of gastric cancer risk even after H.pylori eradication in contrast with the pepsinogen test.",
keywords = "Cancer biomarker, Gastric ulcer, Helicobacter pylori, Pepsinogen test, Trefoil factor",
author = "Mitsuru Kaise and Jun Miwa and Ai Fujimoto and Jun Tashiro and Daisuke Tagami and Hiromi Sano and Yasukazu Ohmoto",
year = "2013",
month = "7",
doi = "10.1007/s10120-012-0185-y",
language = "English",
volume = "16",
pages = "329--337",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test

T2 - Serum trefoil factor 3 is a stable biomarker

AU - Kaise, Mitsuru

AU - Miwa, Jun

AU - Fujimoto, Ai

AU - Tashiro, Jun

AU - Tagami, Daisuke

AU - Sano, Hiromi

AU - Ohmoto, Yasukazu

PY - 2013/7

Y1 - 2013/7

N2 - Background and aim: Emerging data indicate that serum trefoil factors (TFFs), especially TFF3, could be potential biomarkers for gastric cancer risk. We aimed to evaluate the influence of Helicobacter pylori (H. pylori) status and eradication on serum TFFs and the pepsinogen test. Methods: Healthy individuals who underwent a thorough medical checkup were enrolled in study 1, and gastric ulcer patients who undertook H. pylori eradication therapy were enrolled in studies 2 and 3. Serum levels of the TFFs (TFF1, TFF2 and TFF3), H. pylori antibody and pepsinogen test were examined in all studies. In study 3, TFF expressions in biopsy samples of the gastric mucosa were additionally examined before and 2 months after eradication. Results: In 1,260 healthy individuals enrolled in study 1, serum TFF1 and TFF2 levels were markedly different between H. pylori antibody-positive and -negative participants (P < 0.0001). Differences in serum TFF3 levels between H. pylori antibody-positive (5.85 ± 3.93 ng/ml) and -negative subjects (5.27 ± 2.38 ng/ml) were statistically significant (P = 0.002) but small in absolute value. In 178 gastric ulcer patients enrolled in study 2, serum TFF1, TFF2 and positive rates of the pepsinogen test significantly decreased 2 months after H. pylori eradication therapy (P < 0.001). In contrast, serum TFF3 levels and positive rates of high TFF3 levels (≥7 ng/ml) did not significantly change with H. pylori-eradication until 5 years after eradication. In 18 gastric ulcer patients (study 3), TFF1 and TFF2 were mainly expressed in the foveolar epithelium, and TFF2 was additionally expressed in the pyloric glands. These expressions significantly decreased with H. pylori eradication. TFF3s were scarcely expressed in the gastric mucosa except in goblet cells of intestinal metaplasia, which did not change with H. pylori eradication. Conclusion: In serum TFFs and pepsinogen tests, only serum TFF3s were not significantly affected by H. pylori eradication, suggesting that serum TFF3 could be a stable biomarker of gastric cancer risk even after H.pylori eradication in contrast with the pepsinogen test.

AB - Background and aim: Emerging data indicate that serum trefoil factors (TFFs), especially TFF3, could be potential biomarkers for gastric cancer risk. We aimed to evaluate the influence of Helicobacter pylori (H. pylori) status and eradication on serum TFFs and the pepsinogen test. Methods: Healthy individuals who underwent a thorough medical checkup were enrolled in study 1, and gastric ulcer patients who undertook H. pylori eradication therapy were enrolled in studies 2 and 3. Serum levels of the TFFs (TFF1, TFF2 and TFF3), H. pylori antibody and pepsinogen test were examined in all studies. In study 3, TFF expressions in biopsy samples of the gastric mucosa were additionally examined before and 2 months after eradication. Results: In 1,260 healthy individuals enrolled in study 1, serum TFF1 and TFF2 levels were markedly different between H. pylori antibody-positive and -negative participants (P < 0.0001). Differences in serum TFF3 levels between H. pylori antibody-positive (5.85 ± 3.93 ng/ml) and -negative subjects (5.27 ± 2.38 ng/ml) were statistically significant (P = 0.002) but small in absolute value. In 178 gastric ulcer patients enrolled in study 2, serum TFF1, TFF2 and positive rates of the pepsinogen test significantly decreased 2 months after H. pylori eradication therapy (P < 0.001). In contrast, serum TFF3 levels and positive rates of high TFF3 levels (≥7 ng/ml) did not significantly change with H. pylori-eradication until 5 years after eradication. In 18 gastric ulcer patients (study 3), TFF1 and TFF2 were mainly expressed in the foveolar epithelium, and TFF2 was additionally expressed in the pyloric glands. These expressions significantly decreased with H. pylori eradication. TFF3s were scarcely expressed in the gastric mucosa except in goblet cells of intestinal metaplasia, which did not change with H. pylori eradication. Conclusion: In serum TFFs and pepsinogen tests, only serum TFF3s were not significantly affected by H. pylori eradication, suggesting that serum TFF3 could be a stable biomarker of gastric cancer risk even after H.pylori eradication in contrast with the pepsinogen test.

KW - Cancer biomarker

KW - Gastric ulcer

KW - Helicobacter pylori

KW - Pepsinogen test

KW - Trefoil factor

UR - http://www.scopus.com/inward/record.url?scp=84880796014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880796014&partnerID=8YFLogxK

U2 - 10.1007/s10120-012-0185-y

DO - 10.1007/s10120-012-0185-y

M3 - Article

C2 - 22907485

AN - SCOPUS:84880796014

VL - 16

SP - 329

EP - 337

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 3

ER -